NEXALIN TECHNOLOGY INC. - COMMON STOCK

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

27 Jun 2024 21:15:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

26 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

20 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

13 Jun 2024 15:00:00 By Nasdaq GlobeNewswire

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

04 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

03 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

22 May 2024 08:30:00 By Nasdaq GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

09 May 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

25 Apr 2024 10:44:22 By Nasdaq GlobeNewswire

Nexalin Technology CEO Provides Letter to Shareholders

10 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

09 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

04 Apr 2024 13:00:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

02 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

28 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

14 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

13 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

08 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

23 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Unveils Next-Generation HALO™ Clarity

11 Jan 2024 08:30:00 By Nasdaq GlobeNewswire